Goldman Sachs’s Acrivon Therapeutics ACRV Stock Holding History

Goldman Sachs’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Buy	14,920 +178	+1%	+$302	﹤0.01%	6455
2026 Q1	$20.5K	Sell	14,742 -104,680	-88%	-$183K	﹤0.01%	6361
2025 Q4	$288K	Buy	119,422 +99,680	+505%	+$217K	﹤0.01%	5886
2025 Q3	$35.7K	Sell	19,742 -120,313	-86%	-$169K	﹤0.01%	6204
2025 Q2	$167K	Buy	140,055 +82,536	+143%	+$113K	﹤0.01%	5710
2025 Q1	$117K	Sell	57,519 -180,033	-76%	-$969K	﹤0.01%	5755
2024 Q4	$1.43M	Buy	237,552 +39,384	+20%	+$286K	﹤0.01%	4569
2024 Q3	$1.39M	Buy	198,168 +173,784	+713%	+$1.37M	﹤0.01%	4412
2024 Q2	$141K	Buy	+24,384	New	+$196K	﹤0.01%	5345
2023 Q2	–	Sell	-13,718	Closed	-$174K	–	5720
2023 Q1	$174K	Sell	13,718 -25,082	-65%	-$421K	﹤0.01%	5342
2022 Q4	$447K	Buy	+38,800	New	+$493K	﹤0.01%	4934

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's ACRV Position: Q2 2026 in Review

Goldman Sachs increased its Acrivon Therapeutics (ACRV) stake by 1.2% in Q2 2026, buying an estimated $302 and bringing the position to 14,920 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6455.

Goldman Sachs first reported a position in ACRV in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.43M in Q4 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Goldman Sachs held 14,920 shares of Acrivon Therapeutics worth $26.6K as of Q2 2026.
Goldman Sachs bought 178 Acrivon Therapeutics shares in Q2 2026, an estimated $302.
Acrivon Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6455 holding.
Goldman Sachs first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 11 quarters since.
Goldman Sachs's Acrivon Therapeutics position peaked at $1.43M in Q4 2024.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.